BioTech Medics, Inc.
BMCS · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.11 | -0.06 | 0.00 | 1.96 |
| FCF Yield | 0.00% | 1.56% | -0.02% | -0.79% |
| EV / EBITDA | -845.09 | 64.56 | -100.89 | -784.67 |
| Quality | ||||
| ROIC | -0.00% | 0.06% | -0.04% | -0.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.00 | 0.02 | 6.17 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 7,652.17% | 98.14% | -161.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.69 | 0.04 | -0.06 | -0.22 |
| Interest Coverage | 0.00 | -136.69 | -85.60 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |